CH12489 AC - publish.csiro.au · 2 Supplementary 1.2: 13C NMR spectrum of 9 in d 6-DMSO. m/z...

6
1 10.1071/CH12489_AC © CSIRO 2013 Australian Journal of Chemistry 2013, 66(4), 491-499 Synthesis and Radiosynthesis of a Novel PET Fluorobenzyl Piperazine for Melanoma Tumour Imaging; [ 18 F]MEL054. Stephen R. Taylor, A,C Maxine P. Roberts, A,F Naomi A. Wyatt, A Tien Q. Pham, A Daniela Stark, A,D Thomas Bourdier, A,E Peter Roselt, B Andrew Katsifis A,E and Ivan Greguric. A A Life Sciences Division, Australian Nuclear Science and Technology Organisation, Locked Bag 2001, Kirrawee DC, NSW 2232, Australia. B Centre for Molecular Imaging, The Peter MacCallum Cancer Centre, 12 St Andrew's Place, East Melbourne, VIC 3002, Australia. F Corresponding Author: Tel +61 2 9717 9894; Fax +61 2 9717 9262; Email [email protected] Characterisation of 9 Supplementary 1.1: 1 H NMR spectrum of 9 in CDCl 3 .

Transcript of CH12489 AC - publish.csiro.au · 2 Supplementary 1.2: 13C NMR spectrum of 9 in d 6-DMSO. m/z...

Page 1: CH12489 AC - publish.csiro.au · 2 Supplementary 1.2: 13C NMR spectrum of 9 in d 6-DMSO. m/z Supplementary 1.3: LRMS spectrum of 9. Mass Spectroscopy direct infusion result indicated

1

10.1071/CH12489_AC © CSIRO 2013 Australian Journal of Chemistry 2013, 66(4), 491-499 Synthesis and Radiosynthesis of a Novel PET Fluorobenzyl Piperazine for Melanoma Tumour Imaging; [18F]MEL054.

Stephen R. Taylor,A,C Maxine P. Roberts,A,F Naomi A. Wyatt,A Tien Q. Pham,A Daniela Stark,A,D Thomas Bourdier,A,E Peter Roselt,B Andrew KatsifisA,E and Ivan Greguric.A

ALife Sciences Division, Australian Nuclear Science and Technology Organisation, Locked Bag 2001, Kirrawee DC, NSW 2232, Australia. BCentre for Molecular Imaging, The Peter MacCallum Cancer Centre, 12 St Andrew's Place, East Melbourne, VIC 3002, Australia. FCorresponding Author: Tel +61 2 9717 9894; Fax +61 2 9717 9262; Email [email protected]

Characterisation of 9

Supplementary 1.1: 1H NMR spectrum of 9 in CDCl3.

Page 2: CH12489 AC - publish.csiro.au · 2 Supplementary 1.2: 13C NMR spectrum of 9 in d 6-DMSO. m/z Supplementary 1.3: LRMS spectrum of 9. Mass Spectroscopy direct infusion result indicated

2

Supplementary 1.2: 13C NMR spectrum of 9 in d6-DMSO.

Supplementary 1.3: LRMS spectrum of 9. Mass Spectroscopy direct infusion result indicated the presence of intact product at ES+ m/z 368 [M+H]+, 390 [M+Na]+.

m/z60 80 100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 400 420 440 460 480 500

%

0

100

%

0

100

ST1027 ES- 40V 49 (0.494) Cm (33:50) Scan ES- 7.25e562

59

57

69

85

75

83

15711399

89

97 103

143

135115153

412189

171158173

243211197 225 242

347255 293283257 325297

311 339 402366365 379 400

442413426 429 451 456

469 483 487 496

ST1027 ES+ 40V 31 (0.312) Cm (31:50) Scan ES+ 3.81e7390

368

1741461027459 6077

8691 109

129130 155 173 195181273217215 261258249229 283 342327301299 315

366349369

388

391

392406 444

412430 458 488

465472 499

Page 3: CH12489 AC - publish.csiro.au · 2 Supplementary 1.2: 13C NMR spectrum of 9 in d 6-DMSO. m/z Supplementary 1.3: LRMS spectrum of 9. Mass Spectroscopy direct infusion result indicated

Supplementary 1.4: HPLC QC chromatograph of pH8 Ammonium Bicarbonateobtained by integration of the area under the curve.

Supplementary 1.5: HPLC QC chromatograph of pH8 Ammonium Bicarbonate Purity: 97.41obtained by integration of the area under the curve. Equipment used for HPLC QC: Waters 600 controlled Model 60F; AlltimaC18 150 x 4.6 mmµL in CH3OH; solvent condition:(80-0%), D) 100 mM pH8 ammonium bicarbonate (10%) over 20 mins.

HPLC QC chromatograph of 9. Mobile phase ACN/H

pH8 Ammonium Bicarbonate; purity: 99.45%; retention: 16.98 mins. Purity analysis was obtained by integration of the area under the curve.

HPLC QC chromatograph of 9. Mobile phase MeOH/H

onium Bicarbonate Purity: 97.41%; retention: 22.18 mins. Purity analysis was obtained by integration of the area under the curve.

Equipment used for HPLC QC: Waters 600 controlled Model 60F; 150 x 4.6 mm; UV: Waters PDA, model 299, 254 nm; Injection amount: 5

solvent condition: grad 1 mL/min, A) ACN or MeOH (100%), D) 100 mM pH8 ammonium bicarbonate (10%) over 20 mins.

3

hase ACN/H2O/100mM Purity analysis was

hase MeOH/H2O/100mM Purity analysis was

Equipment used for HPLC QC: Waters 600 controlled Model 60F; Column used: 254 nm; Injection amount: 5

rad 1 mL/min, A) ACN or MeOH (10-90%), B) H2O 0%), D) 100 mM pH8 ammonium bicarbonate (10%) over 20 mins.

Page 4: CH12489 AC - publish.csiro.au · 2 Supplementary 1.2: 13C NMR spectrum of 9 in d 6-DMSO. m/z Supplementary 1.3: LRMS spectrum of 9. Mass Spectroscopy direct infusion result indicated

4

Supplementary 1.6: Elemental composition of 9. a)

Page 5: CH12489 AC - publish.csiro.au · 2 Supplementary 1.2: 13C NMR spectrum of 9 in d 6-DMSO. m/z Supplementary 1.3: LRMS spectrum of 9. Mass Spectroscopy direct infusion result indicated

b)

Supplementary 1.7: Schematic diagram of a) synthesis module used to synthesise automated synthesis module used to synthesise

Schematic diagram of a) GE TRACERlab™synthesis module used to synthesise 11; b) in-house modified Nuclear Interface automated synthesis module used to synthesise [18F]9.

5

™ FXFN automated

Nuclear Interface [18F]FDG

Page 6: CH12489 AC - publish.csiro.au · 2 Supplementary 1.2: 13C NMR spectrum of 9 in d 6-DMSO. m/z Supplementary 1.3: LRMS spectrum of 9. Mass Spectroscopy direct infusion result indicated

6

GE TRACERlab FXFN Reactor Nuclear Interface [18F]FDG synthesis module Position Reagents/material Position Reagents/material V1 K2CO3 (2 mg), Kryptofix 2.2.2 (10

mg) in CH3CN/H2O (1 mL, 80:20)

V1

Methanol (1 mL)

V2 Precursor 10 (2 mg) in DMF (1 mL) V3 Precursor 8 (4.5 mg) in CH3OH (0.4 mL) and AcOH (20 µL)

V3 HCl (0.1 M aq, 12 mL) V4 NaCNBH3 (2 mg) in CH3OH (0.4 mL) V4 H2O (5 mL) V5 H2O (2 mL) A Sep-Pak Light QMA D Sep-Pak Plus C18

Supplementary 1.8: Preparation of reagents for the two-step, two-pot automated radiosynthesis of [18F]9 using the GE Tracerlab FXFN and Nuclear Interface [18F]FDG synthesis module.